Lijnen H R, Van Hoef B, Collen D
Center for Thrombosis and Vascular Research, K.U. Leuven, Belgium.
J Biol Chem. 1991 Mar 5;266(7):4041-4.
The reaction between plasminogen activators and plasminogen activator inhibitor-1 is characterized by an initial rapid formation of an inactive reversible complex. The second-order association rate constant (k1) of complex formation of recombinant two-chain tissue-type plasminogen activator (rt-PA) or recombinant two-chain urokinase-type plasminogen activator (rtcu-PA) by recombinant plasminogen activator inhibitor-1 (rPAI-1) is 2.9 +/- 0.4 x 10(7) M-1 s-1 (mean +/- S.D., n = 30) and 2.0 +/- 0.6 x 10(7) M-1 s-1 (n = 12), respectively. Different molecular forms of tissue- or urokinase-type plasminogen activator which do not form covalent complexes with rPAI-1, including rt-PA-Ala478 (rt-PA with the active-site Ser478 mutagenized to Ala) and anhydro-urokinase (rtcu-PA with the active-site Ser356 converted to dehydroalanine) reduced k1 in a concentration-dependent manner, compatible with 1:1 stoichiometric complex formation between rPAI-1 and these ligands. The apparent dissociation constant (KD) of the complex between rPAI-1 and rt-PA-Ala478, determined as the concentration of rt-PA-Ala478 which reduced k1 to 50% of its control value, was 3-5 nM. Corresponding concentrations of active-site-blocked two-chain rt-PA were 150-250-fold higher. The concentration of anhydro-urokinase which reduced k1 to 50% was 4-6 nM, whereas that of active-site-blocked rtcu-PA was 100-250-fold higher. Recombinant single-chain urokinase-type plasminogen activator had an apparent KD of about 2 microM. These results suggest that inhibition of rt-PA or rtcu-PA by rPAI-1 proceeds via a reversible high affinity interaction which does not require a functional active site but which is markedly reduced following inactivation of the enzymes with active-site titrants.
纤溶酶原激活剂与纤溶酶原激活剂抑制剂-1之间的反应特点是最初迅速形成一种无活性的可逆复合物。重组纤溶酶原激活剂抑制剂-1(rPAI-1)与重组双链组织型纤溶酶原激活剂(rt-PA)或重组双链尿激酶型纤溶酶原激活剂(rtcu-PA)形成复合物的二级缔合速率常数(k1)分别为2.9±0.4×10⁷ M⁻¹ s⁻¹(平均值±标准差,n = 30)和2.0±0.6×10⁷ M⁻¹ s⁻¹(n = 12)。组织型或尿激酶型纤溶酶原激活剂的不同分子形式,它们不与rPAI-1形成共价复合物,包括rt-PA-Ala478(活性位点Ser478突变为Ala的rt-PA)和脱水尿激酶(活性位点Ser356转化为脱氢丙氨酸的rtcu-PA),以浓度依赖的方式降低k1,这与rPAI-1和这些配体之间1:1化学计量复合物的形成相一致。rPAI-1与rt-PA-Ala478之间复合物的表观解离常数(KD),定义为使k1降低至其对照值50%时的rt-PA-Ala478浓度,为3 - 5 nM。活性位点被阻断的双链rt-PA的相应浓度高150 - 250倍。使k1降低至50%的脱水尿激酶浓度为4 - 6 nM,而活性位点被阻断的rtcu-PA的浓度高100 - 250倍。重组单链尿激酶型纤溶酶原激活剂的表观KD约为2 μM。这些结果表明,rPAI-1对rt-PA或rtcu-PA的抑制通过可逆的高亲和力相互作用进行,这种相互作用不需要功能性活性位点,但在用活性位点滴定剂使酶失活后会显著降低。